INDIVIDUAL PEPTIDES
Tetrapeptide-7 is an unpalmitoylated four-residue peptide candidate for comfort and facial age-care briefs. Distinguish its identity from Palmitoyl Tetrapeptide-7 before comparing preparation data, requesting material documents or planning a sample and quotation enquiry.
On this page Overview Identity Review Questions Enquire →
- Catalogue reference
- KI-034
- Product family
- Individual peptides
- CAS reference
- 77727-17-4
- Public INCI identity reference
- Tetrapeptide-7
The public overview identifies the catalogue material. Confirm the supplied grade, full composition and current batch specifications in the supplier documents.
Development directions
Comfort and facial age-care concepts require separate endpoints. The identity of an unpalmitoylated tetrapeptide does not establish the effects of a palmitoylated peptide blend or the performance of your complete cosmetic.
Possible formulation formats
- Facial comfort serum screening
- Age-care cosmetic emulsion
- Unmodified-versus-lipidated peptide comparison
Formulation concepts for evaluation. Review the actual supplied material and finished formula for the intended cosmetic use.
Identity and supplied form
The CAS 77727-17-4 reference describes GQPR with a free-acid terminus, also indexed as Rigin. This is distinct from Palmitoyl Tetrapeptide-7. Confirm sequence, terminal form, counterions and peptide content for the offered material.
The palmitoyl prefix changes the material comparison
The public compound record describes the unpalmitoylated GQPR reference. Data for a lipidated derivative or a multi-peptide preparation should not be relabelled as evidence for this material. If a comfort mechanism is central to the brief, request a study matched to the exact peptide and preparation.
Compare the material for your brief
A Palmitoyl Tetrapeptide-7-containing blend can differ in lipid modification, co-peptides, solvent system and peptide content. Compare those fields explicitly. A shared four-residue backbone does not establish equivalent incorporation guidance or finished-formula performance.
Formulation review priorities
| Review point | What to establish |
|---|---|
| Derivative selection | Match unpalmitoylated GQPR versus the palmitoylated derivative. |
| Preparation content | Request the full declaration and peptide-specific content for comparable quotations. |
| Endpoint relevance | Separate sensory comfort, visible appearance and barrier measures in the assessment brief. |
Public reference sources
PubChem: Tetrapeptide-7 / Rigin identity →
GENOPEP: public catalogue reference →
Reference review: 31 October 2026. These public sources describe identity, research or third-party preparations. Confirm the exact offered material and its current documents for your project.
Questions for your brief
- Do you require GQPR or the palmitoylated derivative?
- Which comfort or age-care endpoint is planned?
- What documents, sample quantity and destination are needed?
Is Tetrapeptide-7 the same as Palmitoyl Tetrapeptide-7?
No. The lipid modification changes the material identity. Match the complete name, structure and supplied preparation before comparing evidence or formulation guidance.
Can results from a multi-peptide blend be assigned to this peptide?
A blend result does not isolate the contribution of one peptide. Review the co-actives, vehicle and study design before applying the reference.